Search for content, post, videos

NLS News

Sponsored Content

Drug & Device development

Latest news

BerGenBio extends Phase II trial
BerGenBio extends Phase II trial

The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA

Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.

The latest clinical trials

The latest research news from the Nordic region

Science Article